(MedPage Today) — The FDA approved plozasiran (Redemplo) for the reduction of triglycerides in people with familial chylomicronemia syndrome (FCS), the agency announced.
The small interfering RNA (siRNA) therapy, designed to reduce triglyceride…
Source link : https://www.medpagetoday.com/cardiology/generalcardiology/118604
Author :
Publish date : 2025-11-19 19:33:00
Copyright for syndicated content belongs to the linked Source.
